Alpine Immune Sciences Inc. (NASDAQ: ALPN) shares doubled on Thursday after the company announced a license agreement with AbbVie Inc. (NYSE: ABBV) for its ALPN-101 dual CD28/ICOS costimulation antagonist.
Under the terms of the agreement, Alpine will receive an upfront payment of $60 million and also will be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones.
Note that prior to this move, Alpine Immune Sciences only had a market cap near $90 million.
Additionally, Alpine is eligible to receive tiered royalties on net sales of ALPN-101. In exchange, AbbVie will receive an option to an exclusive license for ALPN-101.
During this option period, Alpine will conduct a phase 2 study in systemic lupus erythematosus. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101.
Note that ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways, which play a big role in multiple autoimmune and inflammatory diseases. Lupus is an example of one of the major diseases that APLN-101 looks to treat.
So far, favorable safety and tolerability, pharmacokinetics and pharmacodynamics have been observed in a first-in-human study in adult healthy volunteers for ALPN-101.
Alpine Immune Sciences stock traded up about 100% early Thursday to $9.74, in a 52-week range of $2.05 to $15.00. The consensus price target is $11.75.
AbbVie stock was relatively flat, at $95.67 in a 52-week range of $62.55 to $99.35. The consensus price target is $100.81.
24/7 Wall St.Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
